
Opinion|Videos|September 3, 2024
Clinical Attributes of Patients Who Would Benefit From Micronized Abiraterone
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Panelists discuss how criteria such as patient comorbidities, disease progression levels, and treatment goals should be considered when selecting the appropriate form of abiraterone for patients with mCRPC, and also explore the potential benefits and drawbacks of using micronized abiraterone in specific patient populations.
Advertisement
Episodes in this series

- In your opinion, what criteria should be considered when selecting the appropriate form of abiraterone for patients with mCRPC?
- What are the potential benefits or drawbacks when using micronized abiraterone in specific patient populations (eg, those with comorbidities or differing levels of disease progression)?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
4
Pearls & Perspectives: Modern Semen Testing and Male Fertility Care, with Thomas Masterson, MD
5






